Equitable Management of Atopic Dermatitis: Treatment Considerations Across Patient Populations
Ryan Haumschild, PharmD, MS, MBA, CPEL; Andrew Alexis, MD, MPH; April W. Armstrong, MD, MPH; Andrew M. Mastro, MS, PA-C; and Mark Makhinson, PharmD, discuss how atopic dermatitis is an immune-mediated disease with heterogeneous pathways that present differently across skin tones, requiring health care professionals to recognize diverse clinical manifestations, address educational gaps in understanding the complex immunopathogenesis, and ensure equitable access to targeted biologic therapies through improved training, clinical trial representation, and coordinated care teams.
Episodes
August 21st 2025EP. 1: Understanding Atopic Dermatitis as an Immune-Mediated Disease
Panelists discuss how atopic dermatitis involves complex inflammatory and neuronal pathways, with IL-4, IL-13, and IL-31 cytokines driving Th2-mediated inflammation that varies across different racial populations.
Panelists discuss how health care professionals face educational gaps in understanding atopic dermatitis (AD) immunopathogenesis, with advanced practice providers (APPS) particularly needing additional training outside standard curricula to master biologic therapy selection.
